Comparison of EsophyX2.0 and MUSE systems for transoral incisionless fundoplication: Technical aspects and outcomes up to 3 years

Sabrina Gloria Giulia Testoni,Giuseppe Pantaleo,Federico Contu,Francesco Azzolini,Lorella Fanti,Pier Alberto Testoni
DOI: https://doi.org/10.1111/den.14810
2024-06-01
Digestive Endoscopy
Abstract:Objectives We compared the efficacy and safety of transoral incisionless fundoplication (TIF) with the EsophyX2.0 and MUSE systems for treatment of gastroesophageal reflux disease (GERD). Methods TIF outcomes from prospective protocols (Esophy2.0X: 2007–2012; MUSE: 2015–2019) were retrospectively compared regarding technical success, moderate/severe adverse events, morpho‐functional findings up to 1 year, and clinical outcomes up to 3 years. Inclusion criteria were: (i) at least 6‐month symptomatic GERD, full/partial response to proton pump inhibitors (PPI), esophagitis, and nonerosive reflux disease/hypersensitive esophagus (both protocols); (ii) hiatal hernia <3 cm (Esophy2.0X) and ≤2.5 cm (MUSE); and (iii) Barrett's esophagus <3 cm (MUSE). Results In the 50 EsophyX2.0 and 46 MUSE procedures, technical success and adverse event rates were similar, but MUSE‐related adverse events (4.4%) were life‐threatening. At 12 months, hiatal hernia recurred more frequently after EsophyX2.0 (P = 0.008). At 6 months, significantly fewer total and acid refluxes were reported after both TIF, but not more significantly at 1 year. Symptoms improved after both TIF up to 1 year (P
gastroenterology & hepatology,surgery
What problem does this paper attempt to address?